Suven Life Sciences begins clinical trial of anti-depressant
New Delhi: Drug firm Suven Life Sciences announced initiation of phase 1 clinical trial and first dosing of a chemical entity intended for the treatment of a major depressive disorder.
In a BSE filing, Suven Life Sciences said its NCESUVN- 911, a “novel chemical entity intended for the treatment of major depressive disorder (MDD) has initiated Phase 1 development and first dosing... and the topline results from the study is expected during the quarter January-March 2018".
Suven Life CEO Venkat Jasti said: “Progression of SUVN-911 into phase 1 clinical development is a significant achievement in enhancing our clinical pipeline beyond Dementia into mental illness arena, Major Depressive Disorder (MDD).”
Suven Life said the global antidepressant market is valued over $20 billion.
Suven Life Sciences shares were trading 1.01 per cent up at Rs. 75.80 on BSE in morning trade.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd